Department of Facial Plastic & Cranio-Maxillo-Facial Surgery, Fakih Hospital, Khaizaran, Lebanon.
Practice for Aesthetic Dermatology, ReSculpt Clinic, Amsterdam, The Netherlands.
Aesthetic Plast Surg. 2022 Feb;46(1):373-381. doi: 10.1007/s00266-021-02479-x. Epub 2021 Aug 2.
Limited data are available describing effectiveness of combining the use of calcium hydroxylapatite (CaHA) and hyaluronic acid (HA).
The authors performed a retrospective chart review of patients injected with a premixed combination of CaHA and a cohesive polydensified matrix (CPM) HA (CaHA:CPM-HA ) in the authors' aesthetic practices. The midface and lower face were injected. Patients' records were evaluated, and treatment results were scored using the Merz Aesthetics Scale for the jawline (clinician rated, CR-MASJ). Adverse events were recorded.
A total of 41 patients were included, all females with a mean age of 47.5 years (range 21-63 years). The mean CR-MASJ score improved from 2.12 at baseline to 0.68 at t = 3 months (SD = 0.69, 95% CI 1.28-1.60) and 1.27 at t = 12 months (SD = 0.74, 95% CI 0.43-0.74). 100% of the subjects had experienced a ≥1-point improvement in CR-MASJ score at t = 3 months, versus 85% at t = 12 months. No adverse events were reported.
The results of this study support the volumizing and lifting potential of the hybrid mix CaHA:CPM-HA for treatment of cheeks and jawline.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
关于联合使用钙羟磷灰石(CaHA)和透明质酸(HA)的有效性,相关数据有限。
作者对在作者的美学实践中注射混合使用钙羟磷灰石和凝聚性高密度基质(CPM)HA 的患者进行了回顾性图表审查。中面部和下面部都进行了注射。评估了患者的记录,并使用 Merz 美学下颌线评估量表(临床医生评分,CR-MASJ)对治疗结果进行评分。记录了不良反应。
共纳入 41 名患者,均为女性,平均年龄 47.5 岁(21-63 岁)。CR-MASJ 评分从基线时的 2.12 分提高到 3 个月时的 0.68 分(SD=0.69,95%CI 1.28-1.60),12 个月时提高到 1.27 分(SD=0.74,95%CI 0.43-0.74)。3 个月时,100%的患者 CR-MASJ 评分提高了 1 分以上,12 个月时为 85%。没有报告不良反应。
这项研究的结果支持混合使用 CaHA:CPM-HA 进行面颊和下颌线治疗的填充和提升潜力。
证据等级 IV:本杂志要求作者为每篇文章分配一个证据等级。有关这些循证医学评级的完整描述,请参阅目录或在线作者指南 www.springer.com/00266 。